LB Pharmaceuticals
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Pennsylvania Plz Ste 1025, New York Ci...Phone Number
(212) 605-0300Website
www.lbpharma.usRevenue
-Stock Symbol
LBRXIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About LB Pharmaceuticals
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. The company is based in New York, NY.Explore more
LB Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is LB Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if LB Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if LB Pharmaceuticals had a recent Job posting/layoffs
LB Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at LB Pharmaceuticals
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on LB Pharmaceuticals recently announced quarterly report
Check out if LB Pharmaceuticals is spiking on competitors!
Product Launch: Get notified when LB Pharmaceuticals launches new products
Funding: Get notified immidiatlly once LB Pharmaceuticals has new funding data
Recommended Actions
Reach out to Masked Content who joined LB Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to LB Pharmaceuticals
Compare insights from companies similar to LB Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
LB Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
LB Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about LB Pharmaceuticals.
LB Pharmaceuticals financials insights
Gather financial insights about LB Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series B
$10M
2024
Series C
$75M
2025
IPO
$285M
LB Pharmaceuticals Tech Stack
A closer look at the technologies used by LB Pharmaceuticals
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Open Position
LB Pharmaceuticals News & Media
LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depressionLB Pharmaceuticals Announces Publication in JAMA Psychiatry of Results from Phase 2 NOVA-1 Trial of LB-102 in Schizophrenia
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the publication in the Journal of the American Medical Association (JAMA) Psychiatry of its manuscript titled “Antipsychotic Efficacy and Safety of LB-102 in the Treatment ofLB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:45 a.m. ET.LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102’s Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)
Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia Multiple SIRS presentations underscore the potential of LB-102 to address positive, negative, and cognitive symptom domains of schizophrenia
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding LB Pharmaceuticals
Sign Up For FreeTo access detailed company insights
LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. The company is based in New York, NY.... Read More
